Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Laurien J Zeverijn"'
Autor:
Soemeya F. Haj Mohammad, Hans J.L. Timmer, Laurien J. Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, Karlijn Verkerk, Florentine A.J. Verbeek, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: The Drug Rediscovery Protocol (DRUP) is a Dutch, pan-cancer, nonrandomized clinical trial that aims to investigate the efficacy and safety of targeted and immunotherapies outside their registered indication in patients with ad
Externí odkaz:
https://doaj.org/article/bde96a8ea019479a9cecb2badbff3c03
Autor:
Karlijn Verkerk, Birgit S. Geurts, Laurien J. Zeverijn, Vincent van der Noort, Henk M.W. Verheul, John B.A.G. Haanen, Astrid A.M. van der Veldt, Ferry A.L.M. Eskens, Maureen J.B. Aarts, Carla M.L. van Herpen, Mathilde Jalving, Jourik A. Gietema, Lot A. Devriese, Mariette Labots, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Egbert F. Smit, Haiko J. Bloemendal
Publikováno v:
The Lancet Regional Health. Europe, Vol 39, Iss , Pp 100875- (2024)
Summary: Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we present RWD
Externí odkaz:
https://doaj.org/article/fc99db69ccab44d8b32b3ad075d188c3
Autor:
Birgit S. Geurts, Thomas W. Battaglia, J. Maxime van Berge Henegouwen, Laurien J. Zeverijn, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Frans L. Opdam, Maja J. A. de Jonge, Geert A. Cirkel, Mariette Labots, Ann Hoeben, Emile D. Kerver, Adriaan D. Bins, Frans G.L. Erdkamp, Johan M. van Rooijen, Danny Houtsma, Mathijs P. Hendriks, Jan-Willem B. de Groot, Henk M. W. Verheul, Hans Gelderblom, Emile E. Voest
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the Drug Rediscovery Protocol (DRUP
Externí odkaz:
https://doaj.org/article/0e6af27c660548eab8d0d86d81fe251d
Autor:
Anouk Bokslag, Anne B. Fons, Laurien J. Zeverijn, Pim W. Teunissen, Christianne J.M. de Groot
Publikováno v:
Hypertension in Pregnancy, Vol 39, Iss 4, Pp 444-450 (2020)
Objective: This study assessed women’s ability to recall different types of hypertensive disorders of pregnancy because of its disproportionate cardiovascular risk later in life. Methods: Participants were 5–10 years post-partum with a history of
Externí odkaz:
https://doaj.org/article/cfa1b9d061ea465eb87367c4797caa5e
Autor:
Natasja L. de Vries, Joris van de Haar, Vivien Veninga, Myriam Chalabi, Marieke E. Ijsselsteijn, Manon van der Ploeg, Jitske van den Bulk, Dina Ruano, Jose G. van den Berg, John B. Haanen, Laurien J. Zeverijn, Birgit S. Geurts, Gijs F. de Wit, Thomas W. Battaglia, Hans Gelderblom, Henk M. W. Verheul, Ton N. Schumacher, Lodewyk F. A. Wessels, Frits Koning, Noel F. C. C. de Miranda, Emile E. Voest
Publikováno v:
Nature, 613(7945), 743-750. Nature Publishing Group
Nature: international weekly journal of science, 613(7945)
Nature: international weekly journal of science, 613(7945)
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB)1,2. Here, in contrast to other cancer types3–5, we observed that 20 ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::378fbf2161d5246e74866cfc1cf6897c
http://www.scopus.com/inward/record.url?scp=85145998988&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85145998988&partnerID=8YFLogxK
Publikováno v:
Cancer Discovery. 12:1634-1641
Ongoing new insights in the field of cancer diagnostics, genomic profiling, and cancer behavior have raised the demand for novel, personalized cancer treatments. As the development of new cancer drugs is a challenging, costly, and time-consuming ende
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea9803257b4af22e42665f32ddd142dd
https://doi.org/10.1158/2159-8290.cd-21-0612
https://doi.org/10.1158/2159-8290.cd-21-0612
Autor:
Tim Schutte, Laurien J Zeverijn, Birgit S Geurts, Gijsbrecht F de Wit, Marleen Kok, Frans L Opdam
Publikováno v:
The Oncologist.
Alpelisib is a specific oral PI3K inhibitor used combined with fulvestrant for the treatment of patients with HR+/HER2–/PIK3CA-mutated metastatic breast cancer. Adverse drug reactions with alpelisib are common, including hyperglycemia and rash. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bd7116b5bf13bb26dd8d5bce90879ec
https://doi.org/10.1093/oncolo/oyad092
https://doi.org/10.1093/oncolo/oyad092
Autor:
Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom, Paul Hamberg, Ann Hoeben, Derk Jan A. de Groot, Mariette Labots, Debbie G.J. Robbrecht, Niven Mehra, Anne M.L. Jansen, Wendy W.J. de Leng, Erik van Werkhoven, Paul Roepman, Laurien J. Zeverijn, Daphne L. van der Velden, J. Maxime van Berge Henegouwen, Louisa R. Hoes, Hanneke van der Wijngaart
Flow chart of patients with BRCA1/2 alterations submitted to the study team between September 2016 and December 2019, and reasons for drop-out, rejection or screen failure. Abbreviations: VUS = Variant of Unknown Significance, LOH = Loss of Heterozyg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65097be0eb5d177688ddeb4db508010b
https://doi.org/10.1158/1078-0432.22481003.v1
https://doi.org/10.1158/1078-0432.22481003.v1
Autor:
Emile E. Voest, Henk M.W. Verheul, Hans Gelderblom, Edwin Cuppen, Martijn P. Lolkema, Hans Morreau, Ann Hoeben, Mariette Labots, Carla M.L. van Herpen, Winette T.A. van der Graaf, Egbert F. Smit, Mathijs P. Hendriks, Laurens V. Beerepoot, Frans Erdkamp, Derk Jan de Groot, Emile D. Kerver, Jan Willem B. de Groot, Eelke H. Gort, Alwin D.R. Huitema, Vincent van der Noort, Erik van Werkhoven, Anne M.L. Jansen, Wendy J. de Leng, Paul Roepman, Joris van de Haar, Daphne L. van der Velden, Laurien J. Zeverijn, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Louisa R. Hoes
Supplementary Figure from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::142be478802724901bf5b4aba218bf7c
https://doi.org/10.1158/1078-0432.22487285.v1
https://doi.org/10.1158/1078-0432.22487285.v1
Autor:
Emile E. Voest, Henk M.W. Verheul, Hans Gelderblom, Edwin Cuppen, Martijn P. Lolkema, Hans Morreau, Ann Hoeben, Mariette Labots, Carla M.L. van Herpen, Winette T.A. van der Graaf, Egbert F. Smit, Mathijs P. Hendriks, Laurens V. Beerepoot, Frans Erdkamp, Derk Jan de Groot, Emile D. Kerver, Jan Willem B. de Groot, Eelke H. Gort, Alwin D.R. Huitema, Vincent van der Noort, Erik van Werkhoven, Anne M.L. Jansen, Wendy J. de Leng, Paul Roepman, Joris van de Haar, Daphne L. van der Velden, Laurien J. Zeverijn, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Louisa R. Hoes
Purpose:Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We hypothesized that patients with rare cancer benefit from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20708b4724c2bca311186b13b326a529
https://doi.org/10.1158/1078-0432.c.6532484
https://doi.org/10.1158/1078-0432.c.6532484